Madison, WI, June 16, 2020 -- Elephas Biosciences Corporation (Elephas), a live tumor imaging company developing novel cancer diagnostic solutions, announced today the appointment of Terry Brady as Chief Financial Officer.
Brady is a seasoned executive with broad experience leading financial departments and an extensive background in leading operations to support scientific innovation. Brady will be responsible for all aspects of establishing and scaling the financial and operating infrastructure of the company.
"We are excited to announce this critical addition to the leadership team," said Maneesh Arora, founder and CEO of Elephas. "Terry’s strong business and accounting background, coupled with his two decades of experience, will be a crucial asset as we build and scale the company”.
A licensed CPA, Brady started his career at KMPG before joining Silverman Consulting and becoming a partner. After leaving Silverman, Brady joined Freedom Graphic System as the Chief Financial Officer. Most recently, he served as the Chief Financial Officer at Farcast Biosciences, a venture-backed oncology diagnostics company.
"While many therapies have been approved to combat the consistent rise in cancer, clinicians still do not have a way to predict with confidence which treatment is best for their patients,” said Brady. "Solving that dilemma and providing better outcomes for cancer patients is at the heart of Elephas’ mission, and that is why I could not be more excited to join this team.”
Brady earned his bachelor’s and master’s degrees in accounting from the University of Notre Dame and an MBA in management, strategy, and operations from Northwestern University – Kellogg School of Management.
About Elephas
Disruption in healthcare is being accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision making and accelerate drug development. We plan to use the power of our platform to deliver a global solution that can revolutionize cancer treatment for every individual. To learn more, visit us at www.elephas.com or follow us on LinkedIn.
Contact
Alison Guzzio
CGLife on Behalf of Elephas
aguzzio@cglife.com
484-459-3243